This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Aplastic and Other Anemias > Efficacy > Other Rare Anemias
Print

In this section:

Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC
Other Rare Anemias

EXJADE Reduces Iron Toxicity
in Other Rare Anemias

Serum ferritin trends in rare anemia patients from the EPIC Study, the largest chelation trial to date

In 2010, the 1-year EPIC study showed that EXJADE effectively reduced serum ferritin levels in patients with rare anemias who suffered from iron toxicity (n=43). These rare anemias primarily included pure red cell aplasia and other hemolytic anemias.1

EXJADE FAQ

Find answers to all of
your EXJADE questions.

Learn more

SAFETY PROFILE
ACROSS ANEMIAS


Learn more
Substantial Reduction in Serum Ferritin Levels2
EXJADE: Substantial Reduction in Serum Ferritin Levels

EXJADE has shown efficacy in reducing iron toxicity with decreased
liver iron concentration levels across rare anemias

In 2007, a 1-year study in patients across a range of anemias (N=184) showed that EXJADE reduced liver iron concentration in patients with other rare anemia patients, which included Fanconi’s and sideroblastic anemia.3

EXJADE Reduces Liver Iron Concentration
in Patients With Rare Anemias2
EXJADE: Reduction in LIC in Patients with Rare Anemias
More Information
Aplastic Anemia Diamond-Blackfan Anemia Other Rare Anemias
EU SmPC

References

  1. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
  2. Data on file. Novartis Pharma AG, Basel, Switzerland.
  3. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed
Substantial Reduction in Serum Ferritin Levels Overall Decrease of -832 pg/L1 Substantial Reduction in Serum Ferritin Levels Overall Decrease of -832 pg/L1 Mean Liver Iron Concentration Reduction from Baseline in Rare Anemias Chart -4.4% Reduction for Patients with Other Anemias at 30 mg Liver Iron Concentration Reduction from Baseline in Rare Anemias Chart -4.4% Reduction for Patients with Other Anemias at 30 mg